Abstract Pharmaceutical industry can be regard as one of the knowledge-intensive industries. Designing a sales promotion for the new medicine really has very great influence on new products to enter the market successfully not only because of its time-consuming and enormously expensive research and development process, but also owing to the government¡¦s control on the production and sales of pharmaceuticals. However, the pharmaceutical products in the domestic market are all generics which are usually lacking of innovation. Therefore, few companies promote their new products through the ¡§New Product Preannouncement¡¨ to raise success rate for the new products. Through the specific case study, my study analyzes and reviews the pluses and minuses of the new product preannouncement activity that Standard Pharmaceutical Company has done with its medicine-grade Cordyceps Sinensis. Moreover, my study also analyzes and reviews whether the preannouncement activity is implemented with thoughtful consideration. In this way, other companies which intend to implement the new product preannouncement activity may take it for reference. The following are the most important conclusions of my study: 1. In the medicine market, new product preannouncement strategy is recommended to raise the success rate for the new products sales. 2. The quality of the new product preannouncement design influences the success rate for the new products sales. 3. While engaging in new product preannouncement, it¡¦s better to depict the functions and attributes of the new products in detail. 4. The first issuer of new generics may implement the new product preannouncement after obtaining the medicine license from National Health Administration. However, the preannouncement activity can be planned in advance. 5. To promote new product preannouncement, 4W2H should be considered at the same time.( 4W means ¡§Who¡¨, ¡§When¡¨, ¡§What¡¨ and ¡§Why¡¨, while 2H represents ¡§How much¡¨ and ¡§How to do¡¨) Keyword¡Gnew product preannouncement, Pharmaceutical industry

Thesis (Ph. D.)--Open University. BLDSC no. DX239030.

Dissertation (Ph.D.)--Auburn University, 2009. / Abstract. Includes bibliographic references.

No description available.

This paper reviews the published literature on the role of pharmacoeconomics for the pharmaceutical industry. Pharmacoeconomics is analysed as a part of decision processes at several stages of drug development and drug marketing. The review is focused on the practices of the application of pharmacoeconomics in various countries in Europe. In particular, the drivers for the development of pharmacoeconomics within the pharmaceutical companies are described. Investments made by companies with respect to the pharmacoeconomic function in terms of personnel and budgets are derived. / Results of literature analysis show, that much is published about the rationale for pharmacoeconomics, and the strength and weakness of different methods used. However there is limited published about the strategic component of pharmacoeconomics from the view of the pharmaceutical industry in Europe and the conclusions drawn from the external influence on pricing and reimbursement on investment and resource allocation into the pharmacoeconomic function. In spite of these restrictions it can be concluded, that the published data show an increasing importance of the pharmacoeconomic function in the pharmaceutical companies in Europe. / Faced with the enormous increase of publications of pharmacoeconomic studies in the last years there is little doubt, that these evaluations are mainly sponsored by the pharmaceutical industry although exact figures are not available. Around 19% of the companies outsourced at least 75% of their budget for pharmacoeconomic evaluations. The pharmacoeconomic staff level tended to increase substantially with company size although the amount of budget is still quite small. About 1% of pharmaceutical research and development was spent for the pharmacoeconomic function. It can be expected that within Europe the pharmacoeconomic function will continue to grow importance in the pharmaceutical industry in the next years. / Thesis (PhDBusinessAdministration)--University of South Australia, 2003.

Thesis (M. P. H.)--University of Hong Kong, 2007. / Also available in print.

Thesis (M.A. in Security Studies (Western Hemisphere))--Naval Postgraduate School, June 2008. / Thesis Advisor(s): Giraldo, Jeanne ; Berger, Marcos. "June 2008." Description based on title screen as viewed on August 27, 2008. Includes bibliographical references (p. 67-72). Also available in print.

Thesis(M.S.)--Auburn University, 2006. / Abstract. Vita. Includes bibliographic references (p.89-92).

Thesis (Ph. D.)--University of Wisconsin--Madison, 1961. / Typescript. Vita. eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references.

Thesis (Ph. D.)--New York University, 2001. / Includes bibliographical references (leaves 337-380).